Published in PLoS One on October 10, 2012
Contrast enhancement in 1p/19q-codeleted anaplastic oligodendrogliomas is associated with 9p loss, genomic instability, and angiogenic gene expression. Neuro Oncol (2013) 0.93
Mitotic index, microvascular proliferation, and necrosis define 3 groups of 1p/19q codeleted anaplastic oligodendrogliomas associated with different genomic alterations. Neuro Oncol (2014) 0.93
Allelic loss of 9p21.3 is a prognostic factor in 1p/19q codeleted anaplastic gliomas. Neurology (2015) 0.87
[(18)F]-fluoro-L-thymidine PET and advanced MRI for preoperative grading of gliomas. Neuroimage Clin (2015) 0.81
Molecular pathogenesis of B-cell posttransplant lymphoproliferative disorder: what do we know so far? Clin Dev Immunol (2013) 0.79
Novel CIC point mutations and an exon-spanning, homozygous deletion identified in oligodendroglial tumors by a comprehensive genomic approach including transcriptome sequencing. PLoS One (2013) 0.78
Chromosome 17p Homodisomy Is Associated With Better Outcome in 1p19q Non-Codeleted and IDH-Mutated Gliomas. Oncologist (2016) 0.75
Characteristics of gliomas in patients with somatic IDH mosaicism. Acta Neuropathol Commun (2016) 0.75
Molecular Testing of Brain Tumor. J Pathol Transl Med (2017) 0.75
The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol (2007) 49.11
IDH1 and IDH2 mutations in gliomas. N Engl J Med (2009) 32.41
Controlling the false discovery rate in behavior genetics research. Behav Brain Res (2001) 21.82
Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases. Cancer Cell (2011) 11.44
IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature (2012) 8.66
Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst (1998) 5.30
Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. J Clin Oncol (2009) 5.06
Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. J Clin Oncol (2006) 4.88
A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma. Cancer Res (2006) 3.83
Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p. Am J Pathol (1994) 3.66
Mutations in CIC and FUBP1 contribute to human oligodendroglioma. Science (2011) 3.49
Integrated study of copy number states and genotype calls using high-density SNP arrays. Nucleic Acids Res (2009) 3.09
DNA methylation, isocitrate dehydrogenase mutation, and survival in glioma. J Natl Cancer Inst (2010) 2.87
All the 1p19q codeleted gliomas are mutated on IDH1 or IDH2. Neurology (2010) 2.53
IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas. Neurology (2010) 2.36
Concurrent CIC mutations, IDH mutations, and 1p/19q loss distinguish oligodendrogliomas from other cancers. J Pathol (2011) 2.27
R/Bioconductor software for Illumina's Infinium whole-genome genotyping BeadChips. Bioinformatics (2009) 1.83
A multilevel model to address batch effects in copy number estimation using SNP arrays. Biostatistics (2010) 1.76
TumorBoost: normalization of allele-specific tumor copy numbers from a single pair of tumor-normal genotyping microarrays. BMC Bioinformatics (2010) 1.70
Identification of der(1;19)(q10;p10) in five oligodendrogliomas suggests mechanism of concurrent 1p and 19q loss. J Neuropathol Exp Neurol (2006) 1.50
Pathogenesis and consequences of uniparental disomy in cancer. Clin Cancer Res (2011) 1.42
A hypermethylated phenotype is a better predictor of survival than MGMT methylation in anaplastic oligodendroglial brain tumors: a report from EORTC study 26951. Clin Cancer Res (2011) 1.40
CIC and FUBP1 mutations in oligodendrogliomas, oligoastrocytomas and astrocytomas. Acta Neuropathol (2012) 1.31
Two types of chromosome 1p losses with opposite significance in gliomas. Ann Neurol (2005) 1.26
Multiplex ligation-dependent probe amplification: a diagnostic tool for simultaneous identification of different genetic markers in glial tumors. J Mol Diagn (2006) 1.09
French brain tumor database: 5-year histological results on 25 756 cases. Brain Pathol (2011) 0.98
Gene amplification is a poor prognostic factor in anaplastic oligodendrogliomas. Neuro Oncol (2008) 0.83
NOTCH2 is neither rearranged nor mutated in t(1;19) positive oligodendrogliomas. PLoS One (2009) 0.82
The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol (2007) 49.11
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol (2009) 25.96
Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med (2007) 13.90
FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol (2003) 12.82
Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med (2006) 10.54
Genome-wide association study identifies five susceptibility loci for glioma. Nat Genet (2009) 7.62
Immunological aspects of cancer chemotherapy. Nat Rev Immunol (2008) 6.61
Radiotherapy for glioblastoma in the elderly. N Engl J Med (2007) 5.64
Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice. Science (2011) 5.62
Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. J Clin Oncol (2009) 5.06
Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. J Clin Oncol (2012) 4.70
The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide. Science (2013) 4.60
An immunosurveillance mechanism controls cancer cell ploidy. Science (2012) 4.35
Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J Exp Med (2005) 4.32
Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 Study. J Clin Oncol (2009) 4.27
Subgroup-specific structural variation across 1,000 medulloblastoma genomes. Nature (2012) 4.13
The anticancer immune response: indispensable for therapeutic success? J Clin Invest (2008) 4.01
5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity. Cancer Res (2010) 3.53
A new alternative mechanism in glioblastoma vascularization: tubular vasculogenic mimicry. Brain (2010) 3.53
Subthalamic nucleus stimulation in severe obsessive-compulsive disorder. N Engl J Med (2008) 3.52
High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytoses. Blood (2012) 3.44
OPA1 mutations induce mitochondrial DNA instability and optic atrophy 'plus' phenotypes. Brain (2007) 3.35
Correlation between O6-methylguanine-DNA methyltransferase and survival in inoperable newly diagnosed glioblastoma patients treated with neoadjuvant temozolomide. J Clin Oncol (2007) 3.23
A novel dendritic cell subset involved in tumor immunosurveillance. Nat Med (2006) 3.21
International Society Of Neuropathology--Haarlem consensus guidelines for nervous system tumor classification and grading. Brain Pathol (2014) 3.21
Primary brain tumours in adults. Lancet (2003) 3.05
Spontaneous and therapeutic prognostic factors in adult hemispheric World Health Organization Grade II gliomas: a series of 1097 cases: clinical article. J Neurosurg (2013) 2.98
Marrow-isolated adult multilineage inducible (MIAMI) cells, a unique population of postnatal young and old human cells with extensive expansion and differentiation potential. J Cell Sci (2004) 2.96
The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy. Immunol Rev (2007) 2.96
Membrane-associated Hsp72 from tumor-derived exosomes mediates STAT3-dependent immunosuppressive function of mouse and human myeloid-derived suppressor cells. J Clin Invest (2010) 2.89
Chemotherapy-triggered cathepsin B release in myeloid-derived suppressor cells activates the Nlrp3 inflammasome and promotes tumor growth. Nat Med (2012) 2.71
The epidemiology of glioma in adults: a "state of the science" review. Neuro Oncol (2014) 2.63
Aquaporin-4 antibody-negative neuromyelitis optica: distinct assay sensitivity-dependent entity. Neurology (2013) 2.59
Angiocentric neuroepithelial tumor (ANET): a new epilepsy-related clinicopathological entity with distinctive MRI. Brain Pathol (2005) 2.46
Continuous growth of mean tumor diameter in a subset of grade II gliomas. Ann Neurol (2003) 2.43
Disrupted surface cross-talk between NMDA and Ephrin-B2 receptors in anti-NMDA encephalitis. Brain (2012) 2.39
Clinical specificities of adult male patients with NMDA receptor antibodies encephalitis. Neurology (2014) 2.38
Treatment of medulloblastoma with postoperative chemotherapy alone: an SFOP prospective trial in young children. Lancet Oncol (2005) 2.37
Primary brain tumours in adults. Lancet (2012) 2.37
Distinct patterns of hematopoietic stem cell involvement in acute lymphoblastic leukemia. Nat Med (2005) 2.36
Beneficial effect of human anti-amyloid-beta active immunization on neurite morphology and tau pathology. Brain (2010) 2.33
DNA methylation in glioblastoma: impact on gene expression and clinical outcome. BMC Genomics (2010) 2.32
A novel genomic signature with translational significance for human idiopathic pulmonary fibrosis. Am J Respir Cell Mol Biol (2015) 2.21
Long-term outcomes of CLIPPERS (chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids) in a consecutive series of 12 patients. Arch Neurol (2012) 2.13
Progressive multifocal leukoencephalopathy in patients with sarcoidosis. Neurology (2014) 2.13
Adenovirus-mediated gene therapy with sitimagene ceradenovec followed by intravenous ganciclovir for patients with operable high-grade glioma (ASPECT): a randomised, open-label, phase 3 trial. Lancet Oncol (2013) 2.08
Contribution of IL-17-producing gamma delta T cells to the efficacy of anticancer chemotherapy. J Exp Med (2011) 2.04
Hyperfractionated versus conventional radiotherapy followed by chemotherapy in standard-risk medulloblastoma: results from the randomized multicenter HIT-SIOP PNET 4 trial. J Clin Oncol (2012) 2.01
Skull-base metastases. J Neurooncol (2005) 2.00
Chemotherapy and radiotherapy: cryptic anticancer vaccines. Semin Immunol (2010) 1.94
Leptomeningeal metastases from solid malignancy: a review. J Neurooncol (2005) 1.94
Prognostic role of FOXP3+ regulatory T cells infiltrating human carcinomas: the paradox of colorectal cancer. Cancer Immunol Immunother (2011) 1.93
MRI monitoring of neuroinflammation in mouse focal ischemia. Stroke (2006) 1.91
Dacarbazine-mediated upregulation of NKG2D ligands on tumor cells activates NK and CD8 T cells and restrains melanoma growth. J Invest Dermatol (2012) 1.90
A uniform activated B-cell-like immunophenotype might explain the poor prognosis of primary central nervous system lymphomas: analysis of 83 cases. Blood (2005) 1.86
Chromosome 7p11.2 (EGFR) variation influences glioma risk. Hum Mol Genet (2011) 1.83
Tumor cell death and ATP release prime dendritic cells and efficient anticancer immunity. Cancer Res (2010) 1.82
Pathologic complete response to neoadjuvant chemotherapy of breast carcinoma is associated with the disappearance of tumor-infiltrating foxp3+ regulatory T cells. Clin Cancer Res (2008) 1.82
T-bet and Eomes instruct the development of two distinct natural killer cell lineages in the liver and in the bone marrow. J Exp Med (2014) 1.82
Treatment of anterior communicating artery aneurysms: complementary aspects of microsurgical and endovascular procedures. J Neurosurg (2003) 1.79
Phenotypic study in 40 patients with dysferlin gene mutations: high frequency of atypical phenotypes. Arch Neurol (2007) 1.76
Anaplastic oligodendrogliomas with 1p19q codeletion have a proneural gene expression profile. Mol Cancer (2008) 1.72
Health-related quality of life in patients treated for anaplastic oligodendroglioma with adjuvant chemotherapy: results of a European Organisation for Research and Treatment of Cancer randomized clinical trial. J Clin Oncol (2007) 1.72
Mutations in FAM111B cause hereditary fibrosing poikiloderma with tendon contracture, myopathy, and pulmonary fibrosis. Am J Hum Genet (2013) 1.70
In situ immune response after neoadjuvant chemotherapy for breast cancer predicts survival. J Pathol (2011) 1.69
Molecular interactions between dying tumor cells and the innate immune system determine the efficacy of conventional anticancer therapies. Cancer Res (2008) 1.69
Identification of regions correlating MGMT promoter methylation and gene expression in glioblastomas. Neuro Oncol (2009) 1.68
BAC array CGH distinguishes mutually exclusive alterations that define clinicogenetic subtypes of gliomas. Int J Cancer (2008) 1.66
Multiminicore disease in a family susceptible to malignant hyperthermia: histology, in vitro contracture tests, and genetic characterization. Arch Neurol (2004) 1.65
Dual role of heat shock proteins as regulators of apoptosis and innate immunity. J Innate Immun (2010) 1.64
Prognostic value of O6-methylguanine-DNA methyltransferase status in glioblastoma patients, assessed by five different methods. J Neurooncol (2009) 1.64
Natural killer cell IFN-gamma levels predict long-term survival with imatinib mesylate therapy in gastrointestinal stromal tumor-bearing patients. Cancer Res (2009) 1.64
Cardiac glycosides exert anticancer effects by inducing immunogenic cell death. Sci Transl Med (2012) 1.63
Quality of life and brain damage after microsurgical clip occlusion or endovascular coil embolization for ruptured anterior communicating artery aneurysms: neuropsychological assessment. J Neurosurg (2009) 1.61
Dynamic imaging response following radiation therapy predicts long-term outcomes for diffuse low-grade gliomas. Neuro Oncol (2012) 1.59
Genetic risk profiles identify different molecular etiologies for glioma. Clin Cancer Res (2010) 1.59
Pilocytic astrocytomas in children: prognostic factors--a retrospective study of 80 cases. Neurosurgery (2003) 1.58
Evaluation of an atlas-based automatic segmentation software for the delineation of brain organs at risk in a radiation therapy clinical context. Radiother Oncol (2007) 1.58
Phase II study of temozolomide without radiotherapy in newly diagnosed glioblastoma multiforme in an elderly populations. Cancer (2004) 1.58